Skip to main
ERAS

Erasca Inc (ERAS) Stock Forecast & Price Target

Erasca Inc (ERAS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 33%
Hold 11%
Sell 11%
Strong Sell 0%

Bulls say

Erasca is a clinical-stage precision oncology company with a pipeline of promising therapies for RAS/MAPK pathway-driven cancers. With two clinical-stage programs and a discovery-stage program, the company has a robust portfolio and potential for blockbuster opportunities in the future. The recent data update and potential for combination therapies with its selective profile make Erasca a strong investment option with potential for growth. Risks to consider include regulatory, commercial, clinical development, manufacturing, financial, liability, and intellectual property.

Bears say

Erasca is a clinical-stage precision oncology company with a focused pipeline targeting RAS/MAPK-driven cancers. Recently, ERAS-0015, a pan-RAS molecular glue, has shown early indications of clinical activity with minimal toxicity and favorable pharmacokinetics, positioning it as a potential best-in-class therapy. However, there are still risks to consider, including regulatory, commercial, and clinical development risks, before the company can fully capitalize on its potential in the market.

Erasca Inc (ERAS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Erasca Inc (ERAS) Forecast

Analysts have given Erasca Inc (ERAS) a Buy based on their latest research and market trends.

According to 9 analysts, Erasca Inc (ERAS) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Erasca Inc (ERAS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.